Clinical trials
Allogeneic Stem Cell Transplantation clinical trials
Below are recruiting allogeneic stem cell transplantation clinical trials, each written for real people, not researchers. We’re tracking 384 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07509749RecruitingPhase 2
New treatments for severe acute GVHD after stem cell transplant
This trial tests new medications for people who develop severe acute graft-versus-host disease (aGVHD) within 100 days after their first stem cell transplant. The goal is to find safer, more effective ways to control aGVHD and improve recovery.
BeijingAges 14 years+ - NCT05887167RecruitingPhase 1
Test safety of making CAR T cells from your own blood
This Phase 1 study looks at whether it is safe and practical to collect your own stem cells and use them to support CAR T-cell therapy for certain blood cancers that have come back or did not respond. It aims to find the best way to combine these steps, which may help some people receive CAR T treatment.
Los Angeles, CaliforniaAges 18–85 - NCT07080775RecruitingPhase 1
Testing a new injection for Parkinson's disease
This trial tests an injection called XS411CN for people with Parkinson's disease whose current medications are not working as well as before. The goal is to see if it is safe and tolerable.
Beijing, Beijing MunicipalityAges 50–75 - NCT06569082Recruiting
Stem cell boost for poor graft function
This study tests whether giving extra stem cells from your original donor can help your blood cell counts recover after a transplant. It is for people whose new immune system has not fully engrafted or whose counts are dangerously low.
New York, New YorkAges 18 years+ - NCT06828796RecruitingPhase 2
Early tacrolimus with half-matched stem cell transplant for blood cancer
This trial tests whether giving tacrolimus early after a half-matched donor stem cell transplant can improve outcomes for patients with blood cancer. The donor must be a family member who shares about half of your HLA markers.
Atlanta, GeorgiaAges 18–80 - NCT06589089RecruitingPhase 2
Stem cell boost after CAR-T for lymphoma
This trial tests giving patients their own stored stem cells after CAR-T therapy to help recover low blood counts. It is for people with B-cell non-Hodgkin lymphoma whose blood counts are still low after CAR-T and who have a stable response to treatment.
ShanghaiAges 18 years+ - NCT01852370Enrolling by invitationPhase 1/Phase 2
Lung and bone marrow transplant plan for immune system disorders
This early-phase study tests a step-by-step transplant approach: first replacing the lungs, then doing a bone marrow (stem cell) transplant to treat certain immune deficiency diseases. It may help people whose immune problem has led to severe, end-stage lung disease.
Pittsburgh, PennsylvaniaAges 5–45 - NCT04099082Recruiting
Predicting lung scarring after a specific viral infection
This study looks at how your immune response to a particular virus (PIV) might predict future lung scarring called bronchiolitis obliterans. It may help doctors better identify who is at higher risk after a stem cell transplant.
Paris, Île-de-France RegionAges 18 years+ - NCT07025538RecruitingPhase 1
Preventing chronic graft-versus-host disease with ruxolitinib
This trial tests whether the drug ruxolitinib, given based on a blood test that predicts risk, can prevent chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It may help people who have a higher risk of developing this complication.
Duarte, CaliforniaAges 18 years+ - NCT03852407RecruitingPhase 2
Two kinds of conditioning before matched stem cell transplant
This trial compares two reduced-intensity conditioning regimens before you receive stem cells from a donor who matches your HLA type. It aims to find which approach works better and is safer for certain blood cancers.
AntwerpAges 18–75 - NCT04742634RecruitingPhase 1/Phase 2
Preemptive drug DEC-C after transplant to reduce hidden cancer
This trial tests whether giving DEC-C (a decitabine-based treatment) soon after an allogeneic transplant can improve outcomes for MDS patients who still have “measurable residual disease” (hidden leftover disease) detectable by a genetic test. It also compares this approach to standard observation if the hidden disease is not detected or if the higher-risk safety checks are not met.
St Louis, MissouriAges 18–75 - NCT06799195RecruitingPhase 2
Better GVHD prevention after stem cell transplant
This trial tests a new approach to prevent graft-versus-host disease (GVHD) after a stem cell transplant from a matched donor. It is for people aged 60 or older with a blood cancer or serious blood disorder who are getting a reduced-intensity conditioning regimen.
Omaha, NebraskaAges 60 years+ - NCT07212335RecruitingEarly Phase 1
Stem cells for low blood counts after CAR-T
This trial tests if umbilical cord stem cells can help restore low blood counts in people with leukemia, lymphoma, or myeloma who still have low blood cell levels three weeks after CAR-T therapy. It aims to improve recovery and reduce infection or bleeding risks.
TianjinAges 18 years+ - NCT02356653RecruitingEarly Phase 1
Stem cell transplant help for children lacking a matching sibling
This expanded-access study offers a specific type of stem cell transplant preparation that removes certain immune cells (CD3 and CD19) from donor stem cells. It is for children who need a transplant but do not have a fully matched sibling donor and whose team cannot use the hospital’s usual matching device protocol.
Philadelphia, PennsylvaniaAges Up to 30 years - NCT07463651RecruitingPhase 3
Gilteritini vs Sorafenib after transplant for FLT3-ITD AML
This trial tests two maintenance drugs (gilteritini and sorafenib) for people with FLT3-ITD positive AML after a stem cell transplant. It compares which drug better prevents relapse using a sensitive test for minimal residual disease (MRD).
Suzhou, JiangsuAges 14–70 - NCT03810196Recruiting
Stem cell addback after transplant to treat viral or fungal infection
This study tests a stem cell “addback” treatment after a specific type of transplant (with certain immune cells removed). It may help the body recover faster and fight serious viral or fungal infections in children and teens.
Philadelphia, PennsylvaniaAges Up to 25 years - NCT06514378RecruitingPhase 1
Safety of stem cells for chronic lung transplant rejection
This trial tests whether a single dose of stem cells given through a bronchoscope is safe for people whose lungs are failing after a transplant. It may help those with a condition called bronchiolitis obliterans syndrome (BOS), a type of chronic rejection that makes it harder to breathe.
MadridAges 18 years+ - NCT04476901RecruitingPhase 2
Study of donor stem cell treatment for non-ischemic heart failure
This Phase 2 trial tests whether donor “MSC” cells can improve heart function in people with non-ischemic dilated cardiomyopathy and reduced pumping strength. You may be eligible if your condition is already treated with standard heart medicines and you can safely undergo a heart catheterization and follow-up testing.
Stanford, CaliforniaAges 18–80 - NCT05401162Recruiting
Chemo with your own stem cells for ovarian cancer
This study looks at giving chemotherapy with an added support step using your own collected stem cells. It may help people with recurrent or metastatic ovarian cancer by supporting bone marrow recovery while treatment continues.
Chongqing, Chongqing MunicipalityAges 18–60 - NCT07237230Recruiting
Gamma-delta T cells to prevent leukemia relapse after transplant
This trial tests if a special type of immune cell called gamma-delta T cells can help prevent acute myeloid leukemia from coming back after a stem cell transplant. It is for people with high-risk features who have recently had a transplant.
Wuhan, HubeiAges 18–65 - NCT05735717RecruitingPhase 2
T-cell transplant using depleted receptors for blood cancers
This Phase 2 study tests a specialized stem cell transplant that removes certain immune “T-cell” receptors to help treat blood cancers like acute leukemia. It may help your body rebuild a healthier immune system after high-dose treatment.
Minneapolis, MinnesotaAges Up to 60 years - NCT05147779RecruitingPhase 1
Stem cell treatment safety study for multiple bladder and sexual conditions
This Phase 1 trial tests whether lab-grown stem cells made from umbilical-cord tissue are safe in people with Peyronie’s disease, erectile dysfunction, or interstitial cystitis. It may help by showing whether this approach is tolerated and safe, before larger studies test how well it works.
St John'sAges Any age - NCT05152368RecruitingPhase 1
Tested umbilical cord stem cell exosomes for trigeminal nerve pain
This Phase 1 study tests whether a treatment made from donated umbilical cord stem cell “exosomes” is safe for people with trigeminal neuralgia (severe facial nerve pain). It mainly focuses on safety and tolerability, and it may help by calming nerve-related pain pathways.
St John'sAges Any age - NCT07479927Recruiting
Online brain training and mindfulness for kids after leukemia treatment
This study tests if a computer-based training program focusing on thinking skills and mindfulness can help children and teens who have had leukemia treatment. It may help improve memory, attention, and emotional well-being.
Madrid, MadridAges 8–18
Hear when a new Allogeneic Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for allogeneic stem cell transplantation?
- Yes. Clin2 currently lists 384 recruiting allogeneic stem cell transplantation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a allogeneic stem cell transplantation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a allogeneic stem cell transplantation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Allogeneic Hematopoietic Stem Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient
- Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- Hematopoietic Stem Cell Transplantation
- Stem Cell Transplantation
- Hematopoetic Stem Cell Transplantation
- Haploidentical Hematopoietic Stem Cell Transplantation
- Autologous Hematopoietic Stem Cell Transplantation
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.